$PLRZ

Polyrizon Ltd.

No enriched coverage for $PLRZ in the last 7 days.

No SEC Form 4 filings for $PLRZ in the last 30 days.

Low

Director at Polyrizon (PLRZ) sells 100 shares, retains 4,069

Polyrizon Ltd. director Carmel Liron reported an open-market sale of 100 Ordinary Shares at $11.00 per share on March 30, 2026. Following this transaction, Liron directly holds 4,069 ordinary shares, which include 1,463 unrestricted shares and 2,606 restricted ordinary shares that vest quarterly conditional on continued service. The filing also clarifies that no derivative securities were involved in this transaction.

Polyrizon (PLRZ) CTO trims stake with 2,917-share open-market sale

Polyrizon Ltd.'s Chief Technology Officer, Tidhar Turgeman, has sold 2,917 Ordinary Shares at $10.90 per share in an open-market transaction, as reported in a recent Form 4 filing. Following this sale, Turgeman directly holds 17,518 Ordinary Shares, which include 18 restricted shares vesting monthly and 17,500 restricted shares vesting quarterly, contingent on his continued employment. The transaction is categorized as a neutral filing impact with a negative sentiment, reflecting a routine insider sale rather than a grant or option exercise.

We're Keeping An Eye On Polyrizon's (NASDAQ:PLRZ) Cash Burn Rate

Polyrizon (NASDAQ:PLRZ) is an unprofitable biotech company currently burning cash, with a cash runway of about 2.5 years based on its US$11m cash reserves and US$4.5m annual burn rate. While its runway is considered reasonable, its cash burn increased by 295% in the last year, which could lead to significant shareholder dilution if it needs to raise more capital. Despite the high burn rate, the company's cash runway provides some comfort to investors.